Bücklein, V., Perez, A., Iacoboni, G., Rejeski, K., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., Frölich, L., Johnson, G., Patel, K., Arciola, B., Schmidt, C., Albanyan, O., Gödel, P., Hoster, E., Bullinger, L., Mackensen, A., Locke, F., von Bergwelt, M., Barba, P., Jain, M. D., & Subklewe, M. (n.d.). p1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE. HemaSphere, 6, 1330–1331. http://access.bl.uk/ark:/81055/vdc_100159757569.0x000008